埃克替尼治疗表皮生长因子受体敏感突变的晚期非小细胞肺癌获益患者的临床分析.docVIP

埃克替尼治疗表皮生长因子受体敏感突变的晚期非小细胞肺癌获益患者的临床分析 　　[摘要]目的 探讨埃克替尼治疗表皮生长因子受体（EGFR）敏感突变的晚期非小细胞肺癌获益患者的临床效果。方法 选取2013年1月～2014年12月来我院治疗的68例EGFR敏感突变的晚期非小细胞肺癌获益患者，采用单双号随机分为甲乙两组，每组34例。给予甲组患者埃克替尼治疗，给予乙组患者吉非替尼治疗，对比观察两组患者总有效率、获益率、体力状况评分及不良反应发生情况。结果 甲组患者总有效率为82.4%，乙组为76.5%，差异有统计学意义（P0.05）；甲组患者不良反应发生率低于乙组（P0.05）。结论 埃克替尼治疗EGFR敏感突变的晚期非小细胞肺癌患者效果显著，且不良反应小，值得临床推广。 　　[关键词]埃克替尼；EGFR敏感突变；晚期非小细胞肺癌 　　[中图分类号] R734.2 [文献标识码] A [文章编号] 1674-4721（2016）10（c）-0059-03 　　[Abstract]Objective To explore clinical effect of Icotinib in treatment of epidermal growth factor receptor （EGFR） sensitive mutations in patients with advanced non-small cell lung cancer benefit.Methods 68 patients of EGFR sensitive mutations with advanced non-small cell lung cancer benefit in our hospital from January 2013 to December 2014 were selected and randomly divided into two groups by using single and double number，34 cases in each group.Group A were given Icotinib treatment，patients in group B were were given Gefitinib treatment，overall effective rate，benefit rate，physical status score and incidence of adverse reactions in two groups were compared and observed.Results Overall effective rate was 82.4% in group A，with 76.5% in group B，and the difference was statistically significant （P0.05），2 years benefit rate was similar between two groups and had no statistical difference （P0.05）；incidence of adverse reactions in group A were lower than those in group B（P0.05）.Conclusion Icotinib in treatment of EGFR sensitive mutation in patients with advanced non-small cell lung cancer has significant effect，and less adverse reactions，it is worthy of clinical promotion. 　　[Key words]Icotinib；EGFR mutation；Advanced non-small cell lung cancer 　　肺癌为临床常见恶性肿瘤之一，具有高发病率、高死亡率[1]。非小细胞肺癌占肺癌发病率的80%，其中75%的非小细胞肺癌患者就诊时已处于中晚期，错过最佳治疗时机，5年生存率很低[2]。使用表皮生长因子受体（epidermal growth factor receptor，EGFR）的酪氨酸激酶抑制剂治疗，能显著延长非小细胞肺癌患者生存期。埃克替尼是我国第一个拥有自主知识产权的小分子靶向抗癌新药物，属于口服酪氨酸激酶受体抑制剂，能够选择性抑制EGFR及其突变体，但对其余激酶均无明显抑制作用，能够显著提高有EGFR突变患者的疗效，有效延长晚期患者生存时间，提高患者生存质量。本文探讨埃克替尼治疗EGF